When will retatrutide be FDA approved?
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
Eli Lilly says it plans to submit the retatrutide BLA to FDA in Q1 2027 based on TRIUMPH Phase 3 readouts. Any approval would come only after FDA review. Retatrutide is not FDA-approved and is not legitimately available today outside clinical trials.
Current Regulatory Status
As of August 24, 2026, retatrutide is an investigational drug — not FDA approved, not available by prescription, and not legally available through compounding pharmacies in the United States.
The TRIUMPH Phase 3 Program
Lilly's initial global registrational TRIUMPH program includes four Phase 3 trials that support potential obesity-related submissions:
- TRIUMPH-1 (NCT05929066) — obesity or overweight without type 2 diabetes, with knee osteoarthritis and obstructive sleep apnea basket trials
- TRIUMPH-2 (NCT05929079) — obesity or overweight with type 2 diabetes, with an obstructive sleep apnea subset
- TRIUMPH-3 (NCT05882045) — severe obesity with established cardiovascular disease
- TRIUMPH-4 (NCT05931367) — obesity or overweight with knee osteoarthritis
Lilly reported positive topline results from TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4, and says it plans a retatrutide BLA submission in Q1 2027 for U.S. approval.
Expected Timeline
- December 11, 2025: TRIUMPH-4 topline results reported in obesity or overweight with knee osteoarthritis
- May 21, 2026: TRIUMPH-1 topline results reported in obesity or overweight without diabetes
- July 23, 2026: TRIUMPH-2 and TRIUMPH-3 topline results reported
- Q1 2027: Lilly-planned BLA submission to FDA
- After submission: FDA review; approval timing is not guaranteed
This timeline assumes no FDA delays, no Complete Response Letter, and no additional safety signals. Biotech timelines are notoriously prone to slippage.
What Phase 2 Results Already Show
The 2023 New England Journal of Medicine Phase 2 obesity trial reported least-squares mean body-weight reductions at 48 weeks of 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group, vs 2.1% with placebo. That 24.2% figure is Phase 2 obesity data, not TRIUMPH-1.
Phase 3 figures should be labeled separately: Lilly reported TRIUMPH-1 12 mg at 28.3% over 80 weeks using the efficacy estimand, TRIUMPH-4 12 mg at 28.7% over 68 weeks using the efficacy estimand in adults with obesity or overweight and knee osteoarthritis, and TRIUMPH-1 extension treatment-regimen results of 28.7% for the 9 mg-to-maximum-tolerated-dose arm at 104 weeks.
Why Retatrutide Matters
Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. This triple mechanism produces larger weight loss than tirzepatide's dual-agonist approach or semaglutide's single GLP-1 activation. If approved, retatrutide will likely set a new standard for obesity pharmacotherapy.
Current Access Paths (Limited)
- Clinical trial enrollment: Check ClinicalTrials.gov for any currently enrolling retatrutide studies; many registrational TRIUMPH trials are no longer recruiting.
- No legitimate compounded retatrutide: Because it is not FDA approved, it cannot be legally compounded for patient use. Vendors selling "compounded retatrutide" are not providing an FDA-regulated product.
- Research-chemical vendors: Many online vendors sell "retatrutide" labeled "research use only." Quality, purity, and actual peptide identity are not assured. Patient safety cannot be guaranteed through these channels.
What About "Compounded Retatrutide" Online?
Operations advertising compounded retatrutide today are misrepresenting the regulatory status. FDA 503A compounding pharmacies can only legally compound drugs that are FDA-approved or on the 503A Bulks List. Retatrutide is neither. Any operation claiming to provide "compounded retatrutide" is either sourcing from gray-market channels, misusing "compounded" terminology, or both. These are not legitimate clinical products.
What Patients Can Do Now
- Optimize current treatment — semaglutide, tirzepatide, or other approved options cover most patients
- Consider clinical trial enrollment if you meet eligibility criteria
- Watch for 2027 approval announcements and commercial launch plans
- Work with a qualified provider on a sustainable obesity management strategy that doesn't depend on unapproved drugs
Reasonable Comparison to Current Options
For context on the rough positioning retatrutide is expected to occupy:
- Semaglutide (Wegovy) — ~15% weight loss
- Tirzepatide (Zepbound) — ~22.5% weight loss
- Retatrutide (investigational) — 24.2% in the Phase 2 obesity trial at 48 weeks; 28.3% in TRIUMPH-1 at 80 weeks using the efficacy estimand
For many patients, current options produce clinically meaningful weight loss. Retatrutide will expand the ceiling, not replace these drugs.
See the retatrutide guide, tirzepatide cost, and semaglutide cost.
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023
- Rosenstock J et al. Retatrutide, a GIP/GLP-1/glucagon receptor agonist, in people with type 2 diabetes (Phase 2). Lancet 2023
- ClinicalTrials.gov — Retatrutide TRIUMPH program
- Drug Shortages — FDA (current shortage status and searchable database)
Related questions about Retatrutide
Find a Retatrutide provider
Browse listed providers offering Retatrutide therapy. Filter by telehealth, location, and insurance acceptance.
Browse providersMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.